Partnership with C2N and The Alzheimer's Trust

Summary by AI BETAClose X

Cambridge Cognition Holdings plc has partnered with C2N Diagnostics and The Alzheimer's Trust to create an integrated pathway for Alzheimer's disease diagnosis in the UK, combining C2N's PrecivityAD2® blood test with Cambridge Cognition's CANTAB Pathway™ digital cognitive assessment platform and The Alzheimer's Trust's phlebotomy and MRI infrastructure. This collaboration aims to accelerate diagnosis and improve patient care, with studies indicating that the combined approach can detect Alzheimer's disease with 90% accuracy, significantly outperforming standard-of-care GP accuracy of 70%. The partnership addresses the urgent need for earlier and more accurate diagnosis in the UK, where dementia is the leading cause of death and diagnostic delays are common.

Disclaimer*

UK 100

Latest directors dealings